Bioequivalence Study of Budesonide From Ekmasonid 9 mg Extended Release FCT (Hikma Pharma, Egypt) Versus Uceris 9 mg Extended Release Tablets (Man. for: Salix Pharm., a Division of Valeant Pharm. LLC, USA, by: Cosmo S.P.A., Italy by License of Cosmo Tech. Ltd., Ireland, Product of France)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 17, 2020

Primary Completion Date

October 1, 2020

Study Completion Date

December 4, 2020

Conditions

Healthy

Interventions

DRUG

Ekmasonid

1 extended release tablet contains 9 mg Budesonide

DRUG

Uceris (first dose)

1 extended release tablet contains 9 mg Budesonide

DRUG

Uceris (second dose)

1 extended release tablet contains 9 mg Budesonide

Trial Locations (1)

Genuine Research Center GRC, Cairo